Patients With Non–[18F]Fludeoxyglucose-Avid Advanced Hepatocellular Carcinoma on Clinical Staging May Achieve Long-Term Recurrence-Free Survival After Liver Transplantation
Authors:
Open Access
- 17 August 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 18 (1) , 53-61
Abstract
There is increasing evidence that a relevant number of patients with hepatocellular carcinoma (HCC) exceeding the Milan criteria may benefit from liver transplantation (LT). We retrospectively analyzed the prognostic significance of [18F]fludeoxyglucose ([18F]FDG) positron emission tomography (PET) for identifying appropriate LT candidates with advanced HCC on clinical staging. Between 1995 and 2008, 111 patients with HCC were listed for LT. All underwent a pretransplant PET evaluation. LT was performed for 91 of these patients. The tumor recurrence rate after LT was 3.6% for patients with non–[18F]FDG-avid (PET−) tumors, but it was 54.3% for patients with [18F]FDG-avid (PET+) tumors (P < 0.001). The 5-year recurrence-free survival rates were comparable for patients with tumors meeting the Milan criteria (86.2%) and patients with PET− HCC exceeding the Milan criteria (81%) at LT, but these rates were significantly higher than the rate for liver recipients with [18F]FDG-avid advanced HCC (21%, P = 0.002). In a multivariate analysis, negative PET findings (odds ratio = 21.6, P < 0.001), an alpha-fetoprotein level P = 0.013), and a total tumor diameter P = 0.022) were identified as pretransplant prognostic variables for recurrence-free survival. A PET+ status was assessed as the only independent clinical predictor of tumor-related patient dropout from the waiting list (hazard ratio = 5.7, P = 0.01). Patients with non–[18F]FDG-avid HCC beyond the Milan criteria according to clinical staging may achieve excellent long-term recurrence-free survival after LT.Keywords
This publication has 40 references indexed in Scilit:
- The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patientsNuclear Medicine Communications, 2010
- Current controversies surrounding liver transplantation for hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2010
- Molecular signature for HCC: role in predicting outcomes after liver transplant and selection for potential adjuvant treatmentCurrent Opinion in Organ Transplantation, 2010
- Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patientsLiver Transplantation, 2010
- Benefit of downsizing hepatocellular carcinoma in a liver transplant populationAlimentary Pharmacology & Therapeutics, 2010
- Beyond Milan criteria – chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosisClinical Transplantation, 2009
- Outcomes of Neoadjuvant Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Before Liver TransplantationAnnals of Surgery, 2008
- Preoperative Assessment of Hepatocellular Carcinoma Tumor Grade Using Needle BiopsyAnnals of Surgery, 2007
- Liver Transplantation for Hepatocellular Carcinoma in Cirrhosis: Is Clinical Tumor Classification before Transplantation Realistic?Transplantation, 2005
- Liver Transplantation for Hepatocellular CarcinomaAnnals of Surgery, 1998